GLAND PHARMA Financial Statement Analysis
|
||
|
The Revenues of GLAND PHARMA have decreased by -17.64% YoY .
The Earnings Per Share (EPS) of GLAND PHARMA has decreased by -1.10 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
GLAND PHARMA Last 5 Annual Financial Results
[BOM: 543245|NSE : GLAND]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹3,625 Cr | ₹4,401 Cr | ₹3,463 Cr | ₹2,633 Cr | ₹2,633 Cr |
| Expenses | ₹2,600 Cr | ₹2,891 Cr | ₹2,161 Cr | ₹1,678 Cr | ₹1,678 Cr |
| Operating Profit (Excl OI) | ₹1,025 Cr | ₹1,510 Cr | ₹1,302 Cr | ₹955 Cr | ₹955 Cr |
| Other Income | ₹240 Cr | ₹224 Cr | ₹135 Cr | ₹139 Cr | ₹139 Cr |
| Interest | ₹7.45 Cr | ₹5.24 Cr | ₹3.41 Cr | ₹7.18 Cr | ₹7.18 Cr |
| Depreciation | ₹147 Cr | ₹110 Cr | ₹99 Cr | ₹95 Cr | ₹95 Cr |
| Profit Before Tax | ₹1,055 Cr | ₹1,619 Cr | ₹1,335 Cr | ₹993 Cr | ₹993 Cr |
| Profit After Tax | ₹781 Cr | ₹1,212 Cr | ₹997 Cr | ₹773 Cr | ₹773 Cr |
| Consolidated Net Profit | ₹781 Cr | ₹1,212 Cr | ₹997 Cr | ₹773 Cr | ₹773 Cr |
| Earnings Per Share (Rs) | ₹46.90 | ₹47.42 | ₹73.75 | ₹60.94 | ₹49.88 |
| PAT Margin (%) | 13.64 | 21.55 | 27.53 | 28.79 | 29.35 |
| ROE(%) | 9.26 | 10.34 | 18.61 | 20.97 | 21.29 |
| ROCE(%) | 13.63 | 14.04 | 24.85 | 28.00 | 27.39 |
| Total Debt/Equity(x) | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 30,881.0 Cr |
| Revenue (TTM) | : | ₹ 5,616.5 Cr |
| Net Profit(TTM) | : | ₹ 698.5 Cr |
| EPS (TTM) | : | ₹ 42.4 |
| P/E (TTM) | : | 44.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLAND PHARMA | 2.3% | 15% | 3.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -0% | -0.4% | 10.2% |
| DIVIS LABORATORIES | 1.4% | 4.1% | 50.3% |
| CIPLA | 0.5% | 1.6% | 1.4% |
| TORRENT PHARMACEUTICALS | -1.2% | 7.1% | 18.3% |
| DR REDDYS LABORATORIES | 1.7% | 1.2% | 1.5% |
| MANKIND PHARMA | 5% | 3.3% | 11% |
| ZYDUS LIFESCIENCES | 1.2% | 4.8% | -7% |
| LUPIN | 2% | -0.9% | 19.8% |
GLAND PHARMA Revenues
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -17.64 % |
| 5 Yr CAGR | 8.32 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹3,625 Cr | -17.64 | |
| Mar2023 | ₹4,401 Cr | 27.08 | |
| Mar2022 | ₹3,463 Cr | 31.51 | |
| Mar2021 | ₹2,633 Cr | 0.00 | |
| Mar2020 | ₹2,633 Cr | - | |
GLAND PHARMA Operating Profit
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -32.14 % |
| 5 Yr CAGR | 1.77 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,025 Cr | -32.14 | |
| Mar2023 | ₹1,510 Cr | 15.97 | |
| Mar2022 | ₹1,302 Cr | 36.29 | |
| Mar2021 | ₹955 Cr | 0.00 | |
| Mar2020 | ₹955 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -17.63 % |
| 5 Yr CAGR | -6.05 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 28.27% | -17.63 | |
| Mar2023 | 34.32% | -8.75 | |
| Mar2022 | 37.61% | 3.67 | |
| Mar2021 | 36.28% | 0.00 | |
| Mar2020 | 36.28% | - | |
GLAND PHARMA Profit After Tax
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -35.54 % |
| 5 Yr CAGR | 0.26 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹781 Cr | -35.54 | |
| Mar2023 | ₹1,212 Cr | 21.54 | |
| Mar2022 | ₹997 Cr | 29.00 | |
| Mar2021 | ₹773 Cr | 0.00 | |
| Mar2020 | ₹773 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -36.71 % |
| 5 Yr CAGR | -17.43 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 13.64 % | -36.71 | |
| Mar2023 | 21.55 % | -21.72 | |
| Mar2022 | 27.53 % | -4.38 | |
| Mar2021 | 28.79 % | -1.91 | |
| Mar2020 | 29.35 % | - | |
GLAND PHARMA Earnings Per Share (EPS)
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -1.10 % |
| 5 Yr CAGR | -1.53 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹47 | -1.10 | |
| Mar2023 | ₹47 | -35.70 | |
| Mar2022 | ₹74 | 21.02 | |
| Mar2021 | ₹61 | 22.17 | |
| Mar2020 | ₹50 | - | |
GLAND PHARMA Return on Capital Employed (ROCE)
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -2.92 % |
| 5 Yr CAGR | -16.01 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 13.63% | -2.92 | |
| Mar2023 | 14.04% | -43.50 | |
| Mar2022 | 24.85% | -11.25 | |
| Mar2021 | 28% | 2.23 | |
| Mar2020 | 27.39% | - | |
GLAND PHARMA Share Price vs Sensex
| Current Share Price | : | ₹1,873.9 |
| Current MarketCap | : | ₹ 30,881.0 Cr |
| Updated EOD on | : | Jul 04,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 2.3% |
15% |
3.4% |
| SENSEX | -0.7% |
3% |
5% |
GLAND PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE HEALTHCARE | 2% | 5.2% | 20.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 2.1% | 4.7% | 13.3% |
| NIFTY MIDSMALLCAP 400 | 0.6% | 3.4% | 3.7% |
| NIFTY MIDCAP 150 | 0.6% | 3% | 4.5% |
| NIFTY 500 EQUAL WEIGHT | 0.5% | 2.9% | 1.9% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | 0.2% | 3.5% | 3.7% |
You may also like the below Video Courses
FAQ about GLAND PHARMA Financials
How the annual revenues of GLAND PHARMA have changed ?
The Revenues of GLAND PHARMA have decreased by -17.64% YoY .
How the Earnings per Share (EPS) of GLAND PHARMA have changed?
The Earnings Per Share (EPS) of GLAND PHARMA has decreased by -1.10 % YoY .
Check out Intrinsic Value of Peers of GLAND PHARMA
Compare Stock Analytics of Peers of GLAND PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
